[Development and prophylactic use of Escherichia coli-smd live vaccine in swine].
This live vaccine was officially accepted and registered in 1976. Based on streptomycin-dependent mutants, it can be efficiently used for prophylaxis against enterotoxaemia and, consequently, help in stabilising production. The vaccine has to be administered subcutaneously to animals aged between two and three weeks and on the day of weaning. Tolerability is localised and generally good. However, differences in effectiveness, so far unexplained, were found to exist between different stocks. The loss of animals was reduced in all stocks which had been prophylatically immunised. The vaccine sould be considered as an intermediate step for immunoprophylaxis against coli-enterotoxaemia.
D000818:Animals; D001428:Bacterial Vaccines / Q000008:administration & dosage / Q000276:immunology; D004926:Escherichia coli / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D004927:Escherichia coli Infections / Q000517:prevention & control*; D009154:Mutation; D013307:Streptomycin / Q000378:metabolism; D013552:Swine; D013553:Swine Diseases / Q000517:prevention & control*
D001428:Bacterial Vaccines; D013307:Streptomycin
Zur Entwicklung und zum Einsatz von Escherichia-coli-smd-Lebendimpfstoff zur Prophylaxe beim Schwein.